1. Effect of labetalol for treating patients with pregnancy-induced hypertension: A systematic review
- Author
-
Punyatoya Bej and Sambhunath Das
- Subjects
eclampsia ,fetal outcome ,labetalol ,maternal outcome ,nifedipine ,preeclampsia ,pregnancy-induced hypertension ,Medicine ,Surgery ,RD1-811 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Pregnancy-induced hypertension (PIH) is one of the main causes of maternal mortality. Many first- and second-line drugs are available to treat the condition. Labetalol lowers blood pressure by blocking both α and β adrenergic receptors. It preserves uteroplacental blood flow efficiently. A systemic review was carried out to find the efficacy and safety of labetalol in the treatment of PIH. Three thousand twenty-six studies were retrieved in 20 years. Finally, 28 studies were selected after applying the review criteria. Twenty-three studies detected that labetalol had superior or similar action compared to other drugs in controlling hypertension in patients with preeclampsia and eclampsia. The systematic review concluded that labetalol is a safe, effective, first-choice of drug with few side effects in treating PIH.
- Published
- 2022
- Full Text
- View/download PDF